RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been named Company of the Year by BioFlorida, in recognition of ADMA’s significant achievements over the past year.
“We are honored to receive this award from BioFlorida and to be recognized for the recent achievements at our Boca Raton, Florida biologics manufacturing and laboratory campus,” stated Adam Grossman, President and Chief Executive Officer. “Over the past year, we were granted two U.S. Food and Drug Administration (“FDA”) biologic product approvals for ASCENIV™ and BIVIGAM®, improved our current good manufacturing practice (“cGMP”) compliance classification with FDA, and secured funding that will support our ongoing commercial product launches and operations. We are extremely proud of these accomplishments and attribute our success to our passionate and dedicated team who worked so hard to revitalize our biologics manufacturing business. We look forward to continuing to contribute to the growing pharma and biotech community in Florida and to continue to expand our operations and grow our workforce to support the increasing demand of our therapeutic products.”